VivoSeq
Oncology

Squamous Cell Carcinoma

251

Pipeline Programs↗

58

Active Trials↗

81

Companies Involved↗

Squamous Cell Carcinoma is a highly competitive landscape with 251 programs across 81 companies. The most active players are Binhui Biopharmaceutical Co., Ltd., Sun Pharma, WestVac Biopharma Co., Ltd.. 15 therapies are approved with 29 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

84/100

Pipeline Velocity

43/100

Mech. Concentration

7/100

Completion Rate

64/100

Attrition Rate

24/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

B

Binhui Biopharmaceutical Co., Ltd.

1 program

Phase 1Sun Pharma logo

Sun Pharma

1 program

Phase 1W

WestVac Biopharma Co., Ltd.

1 program

Phase 1M

Mirati Therapeutics Inc.

1 program

Phase 1T

Tvardi Therapeutics, Incorporated

1 program

Phase 1GSK logo

GSK

5 programs

Phase 2

Pipeline

Programs by Phase

Preclinical12

Bleomycin Sulfate

Sequus Pharmaceuticals

Cetuximab

Imclone

Pregabalin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Celecoxib

Philadelphia Eye Associates

Nimorazole

European Organisation for Research and Treatment of Cancer - EORTC

Phase 141

Alpelisib

Novartis

Olaparib

AstraZeneca

Cabozantinib

Bristol-Myers Squibb

Palbociclib

Pfizer

Sorafenib

Bayer

Phase 2154

Lapatinib

GSK

Methotrexate

Alnylam Pharmaceuticals

Osimertinib

AstraZeneca

Sintilimab

Innovent Biologics (Suzhou) Co. Ltd.

Enfortumab Vedotin

Pfizer

Phase 329

Cemiplimab

Regeneron

Pembrolizumab

Merck & Co.

Nimotuzumab

Biotech Pharmaceutical Co., Ltd.

Toripalimab

Coherus Oncology, Inc.

Carboplatin

Avyxa

Approved15

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Docetaxel

Avyxa

Hydroxyurea

Theravia

Tretinoin

Valeant Pharmaceuticals

Copanlisib

Bayer

Analysis

Modality Breakdown

80%

Small molecule

200 of 250 classified programs — the dominant modality here.

20%ALL OTHERSMonoclonal antibody3916%Protein / enzyme42%Antibody–drug conjugate2<1%Cell therapy2<1%Peptide1<1%Gene therapy1<1%Other1<1%

Small molecule leads; the ring shows all 250 classified programs, each share of the total. Modality classified for 100% of 280 pipeline programs.

Analysis

Trial Status

294

clinical trials

Completed129 · 44%
Terminated53 · 18%
Unknown status34 · 12%
Recruiting24 · 8%
Active, not recruiting21 · 7%
Withdrawn19 · 6%
Other14 · 5%

Clinical Trials

Trial Activity

294 trials

Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial
Recruiting·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT07121595·50 enrolled
Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002)
Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT05098119·43 enrolled
ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma
Recruiting·HHunan Province Tumor Hospital·Phase 2·NCT05014464·90 enrolled
Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
Recruiting·—·Phase 2·NCT03708224·55 enrolled
Carboplatin + Paclitaxel + Cetuximab (PCC) After Failure of Pembrolizumab +/- First-line Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Recruiting·CCentre Paul Strauss·Phase 2·NCT06725368·46 enrolled
Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell Carcinoma
Recruiting·TThe First Affiliated Hospital of Guangzhou Medical University·Phase 2·NCT06383728·51 enrolled
Study of TPEx Followed by a Maintenance With Avelumab and Cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma of the H&N
Recruiting·GGroupe Oncologie Radiotherapie Tete et Cou·Phase 2·NCT06640725·70 enrolled
Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin
Recruiting·—·Phase 2·NCT04204837·61 enrolled
Induction Chemotherapy Combined With Tislelizumab for Locally Advanced Squamous Cell Carcinoma of the External Auditory Canal
Recruiting·EEye & ENT Hospital of Fudan University·Phase 2·NCT07370337·50 enrolled
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
Recruiting·SShanghai Miracogen Inc.·Phase 2·NCT04868162·116 enrolled
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases
Recruiting·RRakuten Medical, Inc.·Phase 3·NCT06699212·412 enrolled
Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05681039·29 enrolled
Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).
Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT05977907·30 enrolled
Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis
Recruiting·MMayo Clinic·Phase 2·NCT06104618·28 enrolled
TIL Therapy in cSCC and MCC
Recruiting·—·Phase 2·NCT07288073·14 enrolled
Page 1 of 20

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)